Key points are not available for this paper at this time.
Design
Editorial
No takes yet. Share an insight, caveat, or question.
Due to prothrombotic risks, coxibs should be restricted to second- or third-line use until definitive cardiovascular safety trials like PRECISION are completed.
Debabrata Mukherjee (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: